by Brandon Tudor | Oct 28, 2025 | Uncategorized
The November 2025 article published in The Journal of Hepatology and titled “Non-invasive tests for MetALD and alcohol-related liver disease” is summarized in what follows, and makes these key points– — Non-invasive tests are available and...
by Brandon Tudor | Oct 24, 2025 | Uncategorized
Here’s a concise summary of the article “Low awareness of Metabolic dysfunction–associated steatotic liver disease (MASLD) among U.S. adults: Trends from National Health and Nutrition Examination Survey (NHANES) 2017–2023” by Alp et al., Hepatology Communications...
by Brandon Tudor | Oct 20, 2025 | Uncategorized
The VA continues to innovate in healthcare generally and liver disease specifically. Including with GLP-1s–“GLP1-RA reduces risk of death in liver disease patients Researchers from VA Orlando and the University of Florida reported Veterans with...
by Brandon Tudor | Oct 11, 2025 | Uncategorized
FROM THE RECENT PAPER regarding diagnostic testing and weight loss medication:”Conclusion: Non-Invasive Tests (NITs) may be used for assessing a treatment response in patients with MASH. Further studies should confirm the treatment effect of NITs and evaluate...
by Brandon Tudor | Oct 9, 2025 | Uncategorized
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today...
